Icosavax Inc (DELISTED) (ICVX:DL)
15.31
0.00 (0.00%)
USD |
NASDAQ |
Feb 29, 16:00
Icosavax Cash from Financing (TTM): 78.07M for Sept. 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 78.07M |
| June 30, 2023 | 78.00M |
| March 31, 2023 | 10.15M |
| December 31, 2022 | 10.31M |
| September 30, 2022 | 0.48M |
| June 30, 2022 | 192.26M |
| Date | Value |
|---|---|
| March 31, 2022 | 191.27M |
| December 31, 2021 | 304.77M |
| September 30, 2021 | 306.22M |
| June 30, 2021 | 119.58M |
| March 31, 2021 | 120.35M |
| December 31, 2020 | 6.638M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.48M
Minimum
Sep 2022
306.22M
Maximum
Sep 2021
118.17M
Average
98.83M
Median
Cash from Financing (TTM) Benchmarks
| Karuna Therapeutics Inc (DELISTED) | 483.37M |
| Immunogen Inc (DELISTED) | 495.80M |
| AbbVie Inc | -211.00M |
| Assure Holdings Corp | 4.07M |
| Harpoon Therapeutics Inc (DELISTED) | 33.00M |